The FDA has approved a stem cell-based therapy for cancer patients from Israeli biotech Gamida Cell that is designed to help them recover more quickly from aggressive chem
More than two years after Mesoblast was poleaxed by the FDA’s rejection of its mesenchymal stem cell therapy for children with graft versus host disease (GvHD), the US reg
Actinium Pharma has revealed the data from its SIERRA trial of radioligand therapy Iomab-B for acute myeloid leukaemia (AML) patients needing a bone marrow transplant, bol
Shares in Omeros plummeted yesterday after the FDA rejected approval of its narsoplimab drug for a rare and life-threatening complication of haematopoietic stem cell transplants (HSCT), say
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio